Peptide therapy · 503A compounded · clinician-prescribed
You've done the research.
Now get the clinical support to go with it.
ojava restore connects you with licensed providers who take peptide therapy seriously — evidence-informed protocols, compounding pharmacies you can trust, and clinicians who won't make you feel like you're asking for something unusual.
This is not a wellness app.
ojava restore is physician and NP-led peptide therapy for people who already understand the science and want proper clinical oversight to go with it.
You know what sermorelin does. You've read the research. You've listened to the episodes. You're not here for an introduction — you're here because you want a licensed provider, a real consult, and compounds sourced from pharmacies that actually test what they make.
That's what we built.
Available through 503A compounding
We'll tell you exactly what we can — and can't — prescribe.
Peptide therapy exists in a regulatory environment that's changing fast. We think you deserve a clear picture. Here's what is currently legal to compound and prescribe through ojava restore.
Available now
Sermorelin
GHRH analog with prior FDA approval. Signals your pituitary to produce its own growth hormone rather than replacing it directly, which preserves the body's natural feedback loops.
Available now
NAD+
On the FDA's 503A approved compounding list. Central to mitochondrial function, cellular energy production, and DNA repair. IM and subcutaneous delivery available depending on protocol.
Available now
Tesamorelin
FDA-approved GHRH analog. The most studied growth-hormone secretagogue in clinical literature, with documented effects on visceral fat reduction and metabolic markers.
Available now
PT-141 (Bremelanotide)
FDA-approved. Acts on melanocortin receptors in the brain rather than the vascular system. Used for sexual dysfunction in both men and women.
Coming up
Some compounds aren't legal yet. We don't pretend otherwise.
BPC-157, CJC-1295/Ipamorelin, TB-500, Thymosin Alpha-1, AOD-9604, and others are currently restricted from 503A compounding under FDA Category 2 designation. HHS has signaled intent to reclassify several of these compounds. Formal publication is pending.
When reclassification lands, we move fast. Join the waitlist and we'll notify you the day legal status changes — alongside notice of when ojava restore opens in your state for the compounds we already prescribe.
Process
Built for people who've already done the homework.
01
Intake & consult
A real video consultation with a licensed provider. Bring labs if you have them. We'll order them if you don't.
02
Protocol design
Compounds, dosing, timing, delivery — built for you. Not a template.
03
Trusted sourcing
FDA-registered 503A compounding pharmacies with third-party potency and sterility testing. This matters more than people realize.
04
Ongoing oversight
Follow-up every 3–4 months. Refills handled efficiently. Protocol adjusted as your data evolves.
Where we draw lines
What we're not.
- We're not a gray-market source with a checkbox consultation.
- We're not going to prescribe restricted compounds until we legally can.
- We're not going to tell you a compound is FDA-approved when it isn't.
- We're not going to waste your time explaining what a peptide is.